Vaidya Sane Ayurved Laboratories logo

Vaidya Sane Ayurved Laboratories financials and balance sheet

NSE: MADHAVBAUGHealthcare Equipment & Supplies

Last close ₹146.45₹0.00 (0.00%)

Share price at the NSE close on 23 Oct 2026. Previous close ₹146.45.

52-week range of traded prices to 23 Oct 2026
₹140.00Low, 21 Oct 2026₹335.00High, 26 Dec 2025
Market cap
₹154 Cr
P/E
17.1
P/B
2.1
Dividend yield
Nonein the last 12 months
ROE
13.4%
Debt to equity
0.04
Volume, NSE
1,600100.0% delivered

3 years at a glance

Consolidated: the company and its subsidiaries together. ₹ crore, years to March.Vaidya Sane Ayurved Laboratories annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
Peak revenue ₹107 Cr, year to Mar 2026A loss in 1 of the 3 years shown

Operating and net margin, per cent

  • Operating margin
  • Net margin

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue107
  2. Materials and goods−19
  3. Employee costs−18
  4. Other expenses−54
  5. Operating profit15
  6. Depreciation−6.1
  7. Other income+2.4
  8. Finance costs−0.8
  9. Profit before tax11
  10. Tax−1.8
  11. Joint ventures0.0
  12. Net profit9.0

What the company owns

  • Plant, investments and other assets₹68 Cr
  • Current investments₹23 Cr
  • Receivables₹10 Cr
  • Inventory₹4 Cr
  • Cash and bank₹0 Cr

What pays for it: net worth and liabilities

  • Net worth₹72 Cr
  • Other liabilities₹24 Cr
  • Owed to suppliers₹7 Cr
  • Borrowings₹3 Cr

Vaidya Sane Ayurved Laboratories business segments, year to Mar 2026

A reportable segment is a line of business the company must report on its own. Consolidated, ₹ crore, as the company reports them.Vaidya Sane Ayurved Laboratories segment results by half year

Revenue by segment

₹100 CrTotal
  • sale of Product Activity₹71.6 Cr71.4% of total
  • Hospital Activity₹28.6 Cr28.6% of total

Profit by segment

  • sale of Product Activity₹17.4 Cr51.6% of total
  • Hospital Activity₹16.4 Cr48.4% of total

Segment results by year

Consolidated from the year to Mar 2026, standalone before, ₹ crore, years to March.

  • sale of Product Activity

    Revenue, ₹ crore
    Profit, ₹ crore
  • Hospital Activity

    Revenue, ₹ crore
    Profit, ₹ crore
₹ croreMar 2025Mar 2026
Revenue of all businesses79100
Company revenue, as in its results87107
Revenue5672
Profit3317
Margin59.7%24.3%
Assets00
Liabilities02
Capital employed0−2
Revenue2329
Revenue87
Profit is before tax and finance costs, the way companies report their segments.

Profit and loss

Consolidated, ₹ crore, years to March.Vaidya Sane Ayurved Laboratories half-yearly results

₹ croreMar 2024Mar 2025Filed 22 MayMar 2026Filed 17 Jun
Revenue from operations9990107
95–91
Materials and goods bought261719
Employee costs27–18
Other expenses42–54
Operating profit before depreciation5–15
Operating margin4.5%–14.4%
Materials, % of revenue25.9%–17.7%
Employee costs, % of revenue27.1%–17.0%
Other expenses, % of revenue42.5%–50.9%
Depreciation and amortisation346
Operating profit after depreciation1–9
Other income222
Finance costs001
Profit before one-off items and tax31111
Profit before tax31011
132
Share of profit of joint ventures and associates000
Net profit079
Net margin0.0%8.0%8.4%
Net margin without joint ventures and associates0.0%8.0%8.4%
Operating expenses, operating profit before depreciation and operating profit after depreciation are left blank for the year to Mar 2025: revenue, other income and exceptional items less the total expenses stated do not come to the profit before tax the same statement states, so the operating expenses cannot be told apart from the rest.

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2025Filed 22 MayMar 2026Filed 17 Jun
6372
6372
Share capital1111
Reserves5261
Belonging to outside owners of subsidiaries00
13
1111
36
Total assets77105
4660
3044
Net debt−16−20
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the year to Mar 2024, so its lines and the ratios worked from it are blank there.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2025Filed 22 MayMar 2026Filed 17 Jun
10.65.4
14.07.5
−0.5−7.6
Receivables−1.8−2.8
Inventories0.4−0.1
Payables−0.20.0
Other working capital1.2−4.8
Tax paid−1.9−2.1
Capital spending8.47.9
Free cash flow2.2−2.5
−10.1−24.0
−0.516.7
Dividends paid0.00.0
Shares issued0.00.0
Net change in cash0.0−1.9
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the year to Mar 2024.

Per share

Consolidated, ₹ per share, years to March.Vaidya Sane Ayurved Laboratories dividend history

₹ per shareMar 2024Mar 2025Filed 22 MayMar 2026Filed 17 Jun
Earnings per share–₹6.76₹8.51
Diluted earnings per share–₹5.81₹8.04
Book value per share–₹59.48₹68.18
Shareholder yield–0.0%0.0%
Market cap at the year end (₹ crore)18399175
RatioMar 2024Mar 2025Filed 22 MayMar 2026Filed 17 Jun
Revenue growth–−9.5%19.0%
Net profit growth––25.3%
Earnings per share growth––25.9%
–11.5%13.4%
––1.9 pts
From the net margin––0.6 pts
From asset turnover––0.1 pts
From borrowing––1.2 pts
Return on capital employed––12.5%
Cash conversion–147.8%60.2%
Interest cover5.5–10.9
Debt to equity–0.020.04
Receivable days–3135
Inventory days–8270
Payable days–150127
Cash conversion cycle, days–−37−21
Working capital days–1335
Asset turnover–1.171.18
Assets per rupee of net worth–1.231.35
Sales per rupee of plant–4.194.87
Capital spending to depreciation–2.031.29
No balance sheet is on record for the year to Mar 2024, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
9.9%
Cash from operations against operating profit
35.1%
Measure3 years
Return on equity, average12.4%
Operating margin, average9.5%
Net margin, average5.5%
Asset turnover, average1.18
Cash conversion cycle, days, average−29
Interest cover, average8.2
Debt to equity, average0.03

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ croreLatest year
Cash from operations5.4
Cash from investing−24.0
Cash from financing16.7
Capital spending7.9
Dividends paid0.0
Shares issued for cash0.0
Borrowings raised1.1
Borrowings repaid0.0

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2024Mar 2025Mar 2026
Receivables growth less revenue growthOur threshold 0 percentage points––16.69
Inventory growth less cost-of-goods growthOur threshold 0 percentage points––−15.84
Other current assets growth less revenue growthOur threshold 5 per cent of revenue––5.33
Effective tax ratePublished threshold 17.16 per cent30.5227.7316.81
Tax charged less tax paid, % of profitOur threshold 10 percentage points–8.79−2.65
A threshold marked as ours has no published figure; it is the line we read the check against.